Please assess the completion status of the following clinical trial:

Trial Title: PT003 MDI Dose Confirmation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~Key Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other inclusion/exclusion criteria as defined in the protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PT003 (Dose 1) (Type: EXPERIMENTAL): PT003 MDI Dose 1
- PT003 (Dose 2) (Type: EXPERIMENTAL): PT003 MDI Dose 2
- PT003 (Dose 3) (Type: EXPERIMENTAL): PT003 MDI Dose 3
- PT003 (Dose 4) (Type: EXPERIMENTAL): PT003 MDI Dose 4
- PT001 (Type: EXPERIMENTAL): PT001 MDI
- PT005 (Type: EXPERIMENTAL): PT005 MDI

Based on this trial design, predict the completion outcome and termination type (if applicable).